Bafna Pharma.

{
  "main_header": {
    "sid": 852453,
    "name": "Bafna Pharma.",
    "stock_name": "Bafna Pharma.",
    "full_name": "Bafna Pharmaceuticals Ltd",
    "name_url": "stocks-analysis/bafna-pharma",
    "exchange": 0,
    "exchangecode": "",
    "primexch": 1,
    "country_id": 34,
    "currency": "INR",
    "cmp": "135.70",
    "chg": 6.45,
    "chgp": "4.99%",
    "dir": 1,
    "prev_price": "129.25",
    "mcapval": "306.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 532989,
    "symbol": "BAFNAPH",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "India SENSEX",
    "isin": "INE878I01022",
    "curr_date": "Apr 17",
    "curr_time": "",
    "bse_nse_vol": "4.74 k",
    "exc_status": "Active",
    "traded_date": "Apr 17, 2026",
    "traded_date_str": "2026 04 17",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/bafna-pharma-852453-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Bafna Pharmaceuticals Declines 6.41% Amid Mixed Signals and Valuation Shift",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/bafna-pharmaceuticals-declines-641-amid-mixed-signals-and-valuation-shift-3952408",
        "imagepath": "",
        "date": "2026-04-18 15:00:05",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>13 Apr:</strong> Stock hits lower circuit amid heavy selling pressure</p>\n                    <p><strong>16 Apr:</strong> Technical and valuation improvements prompt rating upgrade</p>\n                    <p><strong>17 Apr:</strong> Stock surges to upper circuit on strong buying interest</p>\n                    <p><strong>17 Apr:</strong> Valuation shifts signal improved price attractiveness</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.145.00</div></div>\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Close</div><div class=\"sta..."
      },
      {
        "title": "Bafna Pharmaceuticals Ltd Locks at Upper Circuit With 5% Gain — Buyers Queue, Sellers Absent",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/bafna-pharmaceuticals-ltd-hits-upper-circuit-amid-strong-buying-pressure-3950959",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/BafnaPharmaceut_stocks_hitting_upper_circuit_3950959.png",
        "date": "2026-04-17 12:00:09",
        "description": "At Rs 139.45, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Bafna Pharmaceuticals Ltd locked at its upper circuit of 5.0% on 16 Apr 2026, with buyers queuing and no sellers willing to part with shares."
      },
      {
        "title": "Bafna Pharmaceuticals Ltd Upgraded to Sell on Technical and Valuation Improvements",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/bafna-pharmaceuticals-ltd-upgraded-to-sell-on-technical-and-valuation-improvements-3950258",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/BafnaPharmaceut_mojoScore_3950258.png",
        "date": "2026-04-17 08:19:02",
        "description": "Bafna Pharmaceuticals Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 16 Apr 2026, reflecting a nuanced improvement across technical indicators and valuation metrics despite ongoing challenges in financial performance. The micro-cap pharmaceutical company’s Mojo Score rose to 31.0, signalling a cautious but more favourable outlook amid mixed signals from quality and financial trends."
      },
      {
        "title": "Bafna Pharmaceuticals Ltd Valuation Shifts Signal Improved Price Attractiveness",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/bafna-pharmaceuticals-ltd-valuation-shifts-signal-improved-price-attractiveness-3949974",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/BafnaPharmaceut_valuationdot_3949974.png",
        "date": "2026-04-17 08:00:30",
        "description": "Bafna Pharmaceuticals Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has recently undergone a notable shift in its valuation parameters, moving from an expensive to a fair valuation grade. This change, coupled with a downgrade in its overall Mojo Grade from Strong Sell to Sell, invites a closer examination of the company’s price attractiveness relative to its historical metrics and peer group benchmarks."
      },
      {
        "title": "Bafna Pharmaceuticals Ltd Locks at Lower Circuit With 5.0% Loss — Sellers Queue, No Buyers in Sight",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/bafna-pharmaceuticals-ltd-plunges-to-lower-circuit-amid-heavy-selling-pressure-3944453",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/BafnaPharmaceut_stocks_hitting_lower_circuit_3944453.png",
        "date": "2026-04-13 10:00:16",
        "description": "At Rs 133.87, sellers were still queuing — but there were no buyers willing to take the other side. Bafna Pharmaceuticals Ltd locked at its lower circuit of 5.0% on 13 Apr 2026, with unfilled sell orders and a frozen price, signalling a pronounced imbalance in supply and demand."
      },
      {
        "title": "Bafna Pharmaceuticals Surges 32.30%: Valuation Concerns Amid Strong Weekly Rally",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/bafna-pharmaceuticals-surges-3230-valuation-concerns-amid-strong-weekly-rally-3942839",
        "imagepath": "",
        "date": "2026-04-11 15:02:38",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>6 Apr:</strong> Week opens at Rs.109.60</p>\n                    <p><strong>8 Apr:</strong> Sharp 9.99% gain to Rs.120.55</p>\n                    <p><strong>9 Apr:</strong> Hits upper circuit at Rs.132.60 (+10.00%)</p>\n                    <p><strong>10 Apr:</strong> Valuation shifts to expensive amid 9.35% rise to Rs.145.00</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.109.60</div></div>\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Close</div><div class=\"stat-value\">Rs.145.00</div><div class=\"stat-change positive\">+32.30%</div..."
      },
      {
        "title": "Bafna Pharmaceuticals Ltd Valuation Shifts Signal Price Attractiveness Concerns",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/bafna-pharmaceuticals-ltd-valuation-shifts-signal-price-attractiveness-concerns-3940824",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/BafnaPharmaceut_valuationdot_3940824.png",
        "date": "2026-04-10 08:00:44",
        "description": "Bafna Pharmaceuticals Ltd has witnessed a notable shift in its valuation parameters, moving from fair to expensive territory, despite delivering mixed returns relative to the broader market. The micro-cap pharmaceutical player’s price-to-earnings (P/E) ratio now stands at 27.4, surpassing many peers, while its price-to-book value (P/BV) has risen to 3.7, signalling a premium that investors should carefully assess amid the company’s middling profitability metrics and sector dynamics."
      },
      {
        "title": "Bafna Pharmaceuticals Ltd Locks at Upper Circuit With 10% Gain — Buyers Queue, Sellers Absent",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/bafna-pharmaceuticals-ltd-hits-upper-circuit-amid-strong-buying-pressure-3939231",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/BafnaPharmaceut_stocks_hitting_upper_circuit_3939231.png",
        "date": "2026-04-09 10:00:27",
        "description": "At Rs 136.13, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Bafna Pharmaceuticals Ltd locked at its upper circuit of 10% on 09 Apr 2026, with buyers queuing and no sellers willing to part with shares."
      },
      {
        "title": "Bafna Pharmaceuticals Ltd is Rated Strong Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/bafna-pharmaceuticals-ltd-is-rated-strong-sell-3935226",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/BafnaPharmaceut_mojoScore_3935226.png",
        "date": "2026-04-07 10:10:02",
        "description": "Bafna Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 13 March 2026. However, the analysis and financial metrics presented here reflect the stock’s current position as of 07 April 2026, providing investors with the latest insights into the company’s performance and outlook."
      }
    ],
    "total": 303,
    "sid": "852453",
    "stock_news_url": "https://www.marketsmojo.com/news/bafna-pharmaceuticals-852453"
  },
  "announcements": [
    {
      "caption": "Clarification On Price Movement",
      "datetime": "15-Apr-2026",
      "details": "We hereby submit our response to the Clarification sought by the Stock Exchange regarding the movement in the Share Price of the Company.",
      "source": "BSE"
    },
    {
      "caption": "Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018",
      "datetime": "13-Apr-2026",
      "details": "Certificate under Regulation 74(5) of SEBi (DP) Regulations 2018 for the Quarter ended March 31 2026.",
      "source": "BSE"
    },
    {
      "caption": "Clarification sought from Bafna Pharmaceuticals Ltd",
      "datetime": "13-Apr-2026",
      "details": "The Exchange has sought clarification from Bafna Pharmaceuticals Ltd on April 13 2026 with reference to significant movement in price in order to ensure that investors have latest relevant information about the company and to inform the market so that the interest of the investors is safeguarded.<BR><BR>The reply is awaited.",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Bafna Pharmaceuticals Ltd has declared <strong>6%</strong> dividend, ex-date: 19 Sep 13",
          "dt": "2013-09-19",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Bafna Pharmaceuticals Declines 6.41% Amid Mixed Signals and Valuation Shift

2026-04-18 15:00:05

Key Events This Week

13 Apr: Stock hits lower circuit amid heavy selling pressure

16 Apr: Technical and valuation improvements prompt rating upgrade

17 Apr: Stock surges to upper circuit on strong buying interest

17 Apr: Valuation shifts signal improved price attractiveness

Week Open

Rs.145.00

Week Close

Read full news article

Bafna Pharmaceuticals Ltd Locks at Upper Circuit With 5% Gain — Buyers Queue, Sellers Absent

2026-04-17 12:00:09

At Rs 139.45, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Bafna Pharmaceuticals Ltd locked at its upper circuit of 5.0% on 16 Apr 2026, with buyers queuing and no sellers willing to part with shares.

Read full news article

Bafna Pharmaceuticals Ltd Upgraded to Sell on Technical and Valuation Improvements

2026-04-17 08:19:02

Bafna Pharmaceuticals Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 16 Apr 2026, reflecting a nuanced improvement across technical indicators and valuation metrics despite ongoing challenges in financial performance. The micro-cap pharmaceutical company’s Mojo Score rose to 31.0, signalling a cautious but more favourable outlook amid mixed signals from quality and financial trends.

Read full news article

Bafna Pharmaceuticals Ltd Valuation Shifts Signal Improved Price Attractiveness

2026-04-17 08:00:30

Bafna Pharmaceuticals Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has recently undergone a notable shift in its valuation parameters, moving from an expensive to a fair valuation grade. This change, coupled with a downgrade in its overall Mojo Grade from Strong Sell to Sell, invites a closer examination of the company’s price attractiveness relative to its historical metrics and peer group benchmarks.

Read full news article

Bafna Pharmaceuticals Ltd Locks at Lower Circuit With 5.0% Loss — Sellers Queue, No Buyers in Sight

2026-04-13 10:00:16

At Rs 133.87, sellers were still queuing — but there were no buyers willing to take the other side. Bafna Pharmaceuticals Ltd locked at its lower circuit of 5.0% on 13 Apr 2026, with unfilled sell orders and a frozen price, signalling a pronounced imbalance in supply and demand.

Read full news article

Bafna Pharmaceuticals Surges 32.30%: Valuation Concerns Amid Strong Weekly Rally

2026-04-11 15:02:38

Key Events This Week

6 Apr: Week opens at Rs.109.60

8 Apr: Sharp 9.99% gain to Rs.120.55

9 Apr: Hits upper circuit at Rs.132.60 (+10.00%)

10 Apr: Valuation shifts to expensive amid 9.35% rise to Rs.145.00

Week Open

Rs.109.60

Week Close

Rs.145.00

+32.30%Read full news article

Bafna Pharmaceuticals Ltd Valuation Shifts Signal Price Attractiveness Concerns

2026-04-10 08:00:44

Bafna Pharmaceuticals Ltd has witnessed a notable shift in its valuation parameters, moving from fair to expensive territory, despite delivering mixed returns relative to the broader market. The micro-cap pharmaceutical player’s price-to-earnings (P/E) ratio now stands at 27.4, surpassing many peers, while its price-to-book value (P/BV) has risen to 3.7, signalling a premium that investors should carefully assess amid the company’s middling profitability metrics and sector dynamics.

Read full news article

Bafna Pharmaceuticals Ltd Locks at Upper Circuit With 10% Gain — Buyers Queue, Sellers Absent

2026-04-09 10:00:27

At Rs 136.13, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Bafna Pharmaceuticals Ltd locked at its upper circuit of 10% on 09 Apr 2026, with buyers queuing and no sellers willing to part with shares.

Read full news article

Bafna Pharmaceuticals Ltd is Rated Strong Sell

2026-04-07 10:10:02

Bafna Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 13 March 2026. However, the analysis and financial metrics presented here reflect the stock’s current position as of 07 April 2026, providing investors with the latest insights into the company’s performance and outlook.

Read full news article

View All News